Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD) - LARVOL DELTA

Clinical Trial of PCV24 in Adults (clinicaltrials.gov) - P1 | N=170 | Completed | Sponsor: Sinovac Life Sciences Co., Ltd. | Trial primary completion date: Feb 2025 ➔ Aug 2024 | Recruiting ➔ Completed

Trial completion • Trial primary completion date • Infectious Disease • Pneumococcal Infections

STRIDE-13: A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (clinicaltrials.gov) - P3 | N=882 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) (clinicaltrials.gov) - P3 | N=1484 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. (PubMed, Vaccines (Basel)) - P3 | "Co-administration of mRNA-1273 with PPSV23 or PCV15 in healthy adults ≥50 years of age was immunogenic and well tolerated."

Journal • Infectious Disease • Novel Coronavirus Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Clinical Audit of Vaccination in Patients Living with Inflammatory Arthritis and Receiving Specialty Medications (CRA-AHPA 2025) - "Vaccinations against influenza, COVID-19, pneumonia (Prevnar 13/20, Pneumovax-23), and shingles (Shingrix) were reviewed. In this audit we found increased vaccination rates in the nurse clinic and among patients > 65 years old. High vaccination rates observed in the nurse clinic likely resulted from dedicated preventative health protocols, clinical stability of nurse clinic patients, and physician/nursing collaboration. Higher rates of >65 vaccination were likely due to increased vaccine receptiveness of older adults, public coverage and outreach programs (programs focusing on vaccination for patients in congregate living), clinic promotion efforts, and community (family physician, pharmacy) promotion of vaccination."

Clinical • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Rheumatology • Varicella Zoster

Insights into Insurance for Vaccine Coverage Patients on Specialty Medications (CRA-AHPA 2025) - "Full vaccination in the public insurance group were as follows: Influenza (81/132, 61.4%), COVID-19 (99/132, 75.0%), Prevnar 13 or 20 (75/132, 56.8%), Pneumovax 23 (106/132, 80.3%), and Shingrix (41/132, 31.1%). Overall, there were several important findings. The group with the highest vaccination rate across all categories were those possessing two or more insurance plans. Higher rates of influenza and Pneumovax 23 vaccination were seen in the public insurance group, but this is likely due to a majority of this group being older than 65 (age required for free Pneumovax coverage) and the general trend of increased influenza vaccination in older adults.[2] Prevnar and Shingrix vaccination rates were seemingly similar for public and private groups, however sub-group analysis presented an important finding."

Clinical • Reimbursement • US reimbursement • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Rheumatology • Varicella Zoster

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of Utah | Trial completion date: Jan 2027 ➔ Jan 2028 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Small Lymphocytic Lymphoma

Characterization of B Cell Subsets in Pediatric Patients with Humoral Immunodeficiency and Specific Antibody Deficiency (AAAAI-WAO 2025) - "Patients were diagnosed using established criteria, including a deficient immune response following vaccination with a polysaccharide antigen vaccine (Pneumovax)...Nine of the 13 patients (69%) had reduced numbers of switched memory B cells, with this abnormality observed in five out of six patients with genetic conditions (83%) and four out of seven without genetic conditions (57%). Conclusions Patients with specific antibody deficiency (SAD) can have decreased percentages and total numbers of class-switched memory B cells, abnormalities observed in both patients with and without genetic defects."

Clinical • Immunology • Metabolic Disorders • Pediatrics • Primary Immunodeficiency • CD27

Modelling the Epidemiological Impact of Different Adult Pneumococcal Vaccination Strategies in the United Kingdom. (PubMed, Infect Dis Ther) - "Projections revealed that in adults, V116 led to significantly greater reductions in IPD in the 65+ year-old population compared with PCV20 or PPSV23."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

Time of day of vaccination does not influence antibody responses to pneumococcal and annual influenza vaccination in a cohort of healthy older adults. (PubMed, Vaccine) - "This study examined whether diurnal timing of a single dose of Pneumovax® (PPV-23) and seasonal influenza vaccine influenced antibody responses in 140 healthy adults over the age of 50...Although time of day did not influence vaccine immunogenicity in AM and PM cohorts, sustained cohort-wide antibody responses were demonstrated in an older population. Identifying 18 % of the total cohort exhibited suboptimal responses to pneumococcal or influenza vaccines underscores the imperative for enhancing vaccine efficacy within this age group to reduce morbidity and mortality."

Journal • Infectious Disease • Influenza • Pneumococcal Infections • Respiratory Diseases

Establishing a new human pneumococcal standard reference serum, MPRSS-01. (PubMed, mSphere) - "With the development of next-generation PCVs, a new S. pneumoniae reference serum standard was needed to include serotypes beyond the existing 24 in 007sp. In this study, antibody concentrations to 33 pneumococcal serotypes were assigned in a new Merck Pneumococcal Reference Serum Standard (MPRSS-01) using the pneumococcal electrochemiluminescence assay, enabling V116 to maintain the link to the historical human pneumococcal standard reference serum while utilizing the new human pneumococcal reference serum."

Biomarker • Clinical • Journal • Review • Infectious Disease • Pneumococcal Infections • Pneumonia

Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. (PubMed, MMWR Morb Mortal Wkly Rep) - "Options included either 20-valent PCV (PCV20; Prevnar20; Wyeth Pharmaceuticals) or 21-valent PCV (PCV21; CAPVAXIVE; Merck Sharp & Dohme) alone or 15-valent PCV (PCV15; VAXNEUVANCE; Merck Sharp & Dohme) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax23; Merck Sharp & Dohme)...Recommendations for PCVs among adults aged 19-49 years with risk conditions and PCV13-vaccinated adults have not changed from previous recommendations. This report summarizes evidence considered for these recommendations and provides updated clinical guidance for use of PCV."

Journal • Infectious Disease • Pneumococcal Infections

MISP 60528 Pneumococcal Vaccination (clinicaltrials.gov) - P=N/A | N=45 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections • Transplantation

Anti-pneumococcal Vaccine Strategy in Patients with Chronic Lymphocytic Leukemia (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Seema Bhat | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Small Lymphocytic Lymphoma

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns (ASH 2024) - "All 8 centers offered ide-cel while cilta-cel was offered by 6...Other vaccines were given less frequently with Prevnar 20 at 64.3%, Pentavalent (DPT, Hep B, H. influenzae) at 57%, Hep B virus (HBV), RZV, and MCV4 each at 50%. Pneumovax 23 and MMR (live) were recommended by 42.8%, HPV by 35.7%, and VZV (live) by 21.4%...While there are limitations in the generalizability of these practices, these findings demonstrate marked differences in clinical practices across USMIRC centers. Further studies are needed to correlate these practices with downstream infection rates and to allow the development of consensus guidelines for both higher and lower-volume centers."

CAR T-Cell Therapy • Cytomegalovirus Infection • Hematological Disorders • Hematological Malignancies • Hepatitis B • Infectious Disease • Influenza • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • CD4

Immune Reconstitution and Readiness for Vaccination after Pediatric Allogeneic Bone Marrow Transplantation for Hematologic Malignancies (ASH 2024) - "Adequate response to vaccination was defined as antibody specific IgG levels >0.1 IU/mL for tetanus and >1.3 ug/mL for at least 70% of Pneumovax serotypes measured 4 weeks after dose 3 and 4 of these immunizations, respectively. Patient characteristics and baseline HCT factors assessed for association with readiness for revaccination at 8 months included : age, sex, malignancy type, stem cell source, graft manipulation, GVHD status, and receipt of rituximab...This data will inform immune response based re-immunization protocols and equip clinicians to manage expectations about vaccine timing for patients and caregivers. Further studies are needed in this clinical arena with larger sample sizes where detecting significant associations between potential covariates and vaccine readiness may be more apparent."

Clinical • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Oncology • Pediatrics • Pneumococcal Infections • Tetanus • Transplantation • CD4

Phase I Clinical Trial of PCV24 in Adults (clinicaltrials.gov) - P1 | N=168 | Recruiting | Sponsor: Sinovac Life Sciences Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns (ASH 2024) - "All centers offered both teclistamab and talquetamab, and 7 also used elranatamab...Other vaccines were used less frequently : Prevnar 20 (33%), Pentavalent (DPT, Hep B, H.influenzae) (27%), Hep B virus (27%), RZV (27%), MCV4 (20%), Pneumovax 23 (20%), HPV (20%), MMR live (20%) and VZV live (6%)...While there are limitations in the generalizability of these practices, these findings demonstrate several areas with varying clinical practices across USMIRC centers. Further studies are needed to correlate these practices with infection rates and to allow development of consensus guidelines for both academic and community centers."

Cytomegalovirus Infection • Hematological Disorders • Hematological Malignancies • Hepatitis B • Infectious Disease • Influenza • Multiple Myeloma • Neutropenia • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • CD4

Extension Safety and Immunogenicity Study of GPNV-001 (clinicaltrials.gov) - P1/2 | N=60 | Completed | Sponsor: GPN Vaccines | Recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: University of California, Davis | Trial completion date: Mar 2025 ➔ Jul 2025 | Trial primary completion date: Mar 2025 ➔ Jul 2025

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: University of California, Davis | Trial completion date: Mar 2024 ➔ Mar 2025 | Trial primary completion date: Mar 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Rheum to Improve: Have Patients Attending the Young Adult Systemic Erythematosus (YASLE) Clinic Received All Appropriate Vaccinations? A Quality Improvement Initiative (ACR Convergence 2024) - "Of the 36 patients whose records were available, only one (2.7%) received the Pneumococcal polysaccharide vaccine (Pneumovax 23®), six (16.7%) received the Pneumococcal conjugated vaccine (PCV13®), and two (5.6%) received the Pneumococcal 20-valent conjugate vaccine (Prevanar 20®)... These findings confirm our hypothesis of suboptimal scheduled and recommended vaccinations in young patients with cSLE who have transitioned to adult care. Furthermore, we have learned that ascertaining vaccination status is time-consuming and ineffective. Given the gaps in vaccination evident from this pursuit, we plan to collaborate with a clinical pharmacist, and with primary care providers, to administer the vaccines of highest priority during follow-up visits at the YASLE clinic."

Clinical • Hepatitis B • Hepatology • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Influenza • Lupus • Measles • Meningococcal Infections • Mumps • Oncology • Pneumococcal Infections • Respiratory Diseases • Rubella • Systemic Lupus Erythematosus • Varicella Zoster

Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States. (PubMed, Infect Dis Ther) - "These results demonstrated that using V116 in adults aged ≥ 65 years in the US can prevent a substantial number of PD cases and deaths while remaining highly favorable economically over a wide range of inputs and scenarios."

Cost effectiveness • HEOR • Journal • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

SYMMETRICAL DRUG-RELATED INTERTRIGINOUS AND FLEXURAL EXANTHEMA (SDRIFE) FOLLOWING FIRST ADMINISTRATION OF IMMUNOGLOBULIN REPLACEMENT (ACAAI 2024) - "Case Description: A 34-year-old female with history of multiple sclerosis on rituximab therapy was initially evaluated for hypogammaglobulinemia with recurrent upper respiratory infections. Workup revealed decreased immunoglobulin G (IgG) of 466 mg/dl, absent titers to streptococcus pneumoniae and haemophilus influenza without improvement following Pneumovax challenge...Emergency room evaluation with Dermatology evaluation revealed normal blood counts and chemistries with elevated C-reactive protein suggestive of a diagnosis of SDRIFE that was treated with a prednisone taper...This case describes the second reported SDRIFE resulting from IVIG and is the first to describe successful avoidance of exanthem on subsequent exposures. With the change to Gamunex from Privigen formulation, the patient has tolerated the recommended treatment without further complications and remains infection free."

CNS Disorders • Dermatology • Infectious Disease • Influenza • Multiple Sclerosis • Pneumococcal Infections • Pneumonia • Respiratory Diseases • CRP

COMPARISON OF NORMAL VS INTENSIFIED VACCINE REGIMENS AGAINST PNEUMOCOCCUS IN CD PATIENTS UNDER BIOTHERAPY: A PROSPECTIVE, MULTICENTER, RANDOMIZED, OPEN-LABEL PNEUMOMICI STUDY (UEGW 2024) - P2b | "Aims & This is a prospective, multicenter, randomized study comparing two vaccine regimens: intensified vaccine strategy (Prevenar13®/Prevenar13®/PSV-23® (or Pneumovax as a replacement for PSV-23) vs. normal strategy (Prevenar13®/PSV-23® (or Pneumovax as a replacement for PSV-23), (randomization 1: 1) on vaccine immunogenicity measured by antibody titer against at least 9 of the 13 pneumococcal serotypes contained in Prevenar13®...Around 88% of patients were under anti-TNF monotherapy (28% on combotherapy) and 12% under vedolizumab... In IBD on biotherapy and/or IS, the intensified pneumococcal vaccine regimen (2 injections of Prevenar followed by one of Pneumo 23) is significantly more immunogenic than a standard regimen, especially when using functional correlate of protection. The duration of the response is also greater in this intensified arm."

Clinical • CNS Disorders • Depression • Gastroenterology • Infectious Disease • Inflammatory Bowel Disease • Pneumococcal Infections • Psychiatry